HEPA · XBRL financial data
Hepion Pharmaceuticals financial statements, every fiscal year
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (HEPA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 0 | 0 | 0 | 0 | — | — |
| Research and development | 11,997 | 20,395 | 33,269 | 35,640 | 11,847 | 446 |
| General and administrative | 8,149 | 10,008 | 10,348 | 9,618 | 7,499 | 3,315 |
| Total operating expenses | 20,146 | 30,403 | 45,489 | 48,448 | 19,347 | 4,164 |
| Operating income (loss) | (20,146) | (30,403) | (45,489) | (48,448) | (19,347) | (4,164) |
| Interest expense | 31 | 9 | 10 | 9 | — | — |
| Income tax expense (benefit) | 31 | 0 | (2,884) | (409) | (2,969) | — |
| Net income (loss) | (20,354) | (32,722) | (42,200) | (48,926) | (13,192) | (8,278) |
| Earnings per share, basic‡ USD per share | (84.00) | (18.80) | (23.60) | (12.32) | (107.35) | (0.88) |
| Earnings per share, diluted‡ USD per share | (84.00) | (18.80) | (23.60) | (12.32) | (107.35) | (0.88) |
| Weighted average shares, basic‡ thousands of shares | 242 | 1,757 | 1,906 | 3,971 | 123 | 9,409 |
| Weighted average shares, diluted‡ thousands of shares | 242 | 1,757 | 1,906 | 3,971 | 123 | 9,409 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-2 stock split (March 2023); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (May 2023); filings made before it reported them unadjusted.
- † Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (HEPA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 40,727 | 91,349 | 51,189 | 14,786 | 406 | 1,828 |
| Prepaid and other current assets | — | — | 5,307 | 2,702 | — | — |
| Total current assets | 42,634 | 97,452 | 56,496 | 17,488 | 1,614 | 3,070 |
| Property and equipment, net | 108 | 153 | 82 | 29 | — | — |
| Right-of-use asset | 556 | 304 | 51 | 213 | — | 0 |
| Goodwill | 1,871 | 1,871 | 0 | — | — | — |
| Total assets | 48,645 | 103,552 | 60,244 | 18,094 | 1,614 | 3,070 |
| Accounts payable | 3,722 | 2,446 | 2,666 | 2,349 | 220 | 168 |
| Accrued liabilities | 660 | 2,506 | 4,800 | 2,439 | 24 | 78 |
| Current portion of long-term debt | 0 | — | — | — | — | — |
| Total current liabilities | 4,662 | 8,206 | 7,886 | 5,290 | 3,144 | 299 |
| Lease liability, non-current | 296 | 50 | 0 | 93 | — | — |
| Total liabilities | 8,125 | 10,557 | 10,389 | 10,814 | 3,477 | 402 |
| Accumulated deficit | (104,105) | (133,501) | (175,701) | (224,627) | (237,820) | (246,098) |
| Total stockholders' equity | 40,520 | 92,995 | 49,856 | 7,281 | (1,863) | 2,668 |
| Total liabilities and equity | 48,645 | 103,552 | 60,244 | 18,094 | 1,614 | 3,070 |
| Common shares outstanding (cover page)‡ thousands of shares | 1,906 | 1,906 | 1,906 | 5,472 | 10,975 | 11,620 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-2 stock split (March 2023); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (May 2023); filings made before it reported them unadjusted.
- † Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (HEPA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (20,354) | (32,722) | (42,200) | (48,926) | (13,192) | (8,278) |
| Stock-based compensation | 2,379 | 4,669 | 2,553 | 1,340 | 792 | 21 |
| Depreciation and amortization | 35 | 86 | 77 | 67 | 31 | — |
| Net cash from operating activities | (16,165) | (31,224) | (34,961) | (40,889) | (18,216) | (3,272) |
| Purchases of property and equipment | 88 | 130 | 16 | 14 | — | — |
| Net cash from investing activities | (86) | (130) | (14) | (14) | (600) | (132) |
| Proceeds from issuing common stock | 42,866 | 82,154 | 0 | 4,495 | 2,500 | 9,000 |
| Proceeds from long-term debt | 177 | 0 | — | — | — | — |
| Repayments of long-term debt | 0 | 177 | 0 | — | — | — |
| Net cash from financing activities | 43,055 | 81,977 | (5,138) | 4,495 | 4,350 | 4,825 |
| Net change in cash | 26,804 | 50,622 | (40,160) | (36,403) | (14,379) | 1,422 |
- † Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals | 1,629 | not reported | (1,394)* | 90.2M | 1.2 quarters | 10-QJun 30, 2026 |
| China Foods Holdings | 16 | 0 | (94)* | 20.3M | 0.2 quarters | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
| Twinlab Consolidated Holdings | 13 | not reported | (907)* | 259.1M | 0.0 quarters | 10-KDec 31, 2024 |
| Regen BioPharma | 0.2 | 59 | (24)* | 1.7B | 0.0 quarters | 10-QJun 30, 2026 |
| Nutra Pharma | not reported | 34 | (251)* | 7.2B | 0.1 quarters | 10-QJun 30, 2026 |
| Evofem Biosciences | 285 | 2,633 | (3,140)* | 132.5M | 0.1 quarters | 10-QJun 30, 2026 |
| Agentix | 0 | not reported | (26) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
| International Stem Cell | 1,089 | 2,675 | 167* | 8.0M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.